Discover and read the best of Twitter Threads about #FridayReport
Most recents (3)
Our latest #FridayReport COVID update is now available featuring:
- Autumns boosters: over 10m now boosted
- protection against Omicron from boosters and prior infection
- AZ nasal vaccine disappoints
- Pfizer bivalent vaccine approved in USA for age 5-11
covidactuaries.org/2022/10/28/fri…
- Autumns boosters: over 10m now boosted
- protection against Omicron from boosters and prior infection
- AZ nasal vaccine disappoints
- Pfizer bivalent vaccine approved in USA for age 5-11
covidactuaries.org/2022/10/28/fri…
Also featured:
- Moderna bivalent booster outperforms original
- pre-Omicron infections don’t compromise immunity against Omicron
- Over 300 Omicron sublineages globally. BA.5 dominant but BQ.1 displacing it
- Evusheld available privately - at a price
covidactuaries.org/2022/10/28/fri…
- Moderna bivalent booster outperforms original
- pre-Omicron infections don’t compromise immunity against Omicron
- Over 300 Omicron sublineages globally. BA.5 dominant but BQ.1 displacing it
- Evusheld available privately - at a price
covidactuaries.org/2022/10/28/fri…
Also featured:
- NHS waiting list nears 7.5 million
- Analysis of Long COVID in Scotland and 22 countries
- latest ONS infections update
- hospital admissions currently falling
- Excess mortality remains high
covidactuaries.org/2022/10/28/fri…
- NHS waiting list nears 7.5 million
- Analysis of Long COVID in Scotland and 22 countries
- latest ONS infections update
- hospital admissions currently falling
- Excess mortality remains high
covidactuaries.org/2022/10/28/fri…
No #FridayReport this week but for weekend reading the latest edition of @TheActuaryMag is a “two years on” pandemic special.
This thread highlights some articles that might be of interest.
theactuary.com/issues/2022/04…
This thread highlights some articles that might be of interest.
theactuary.com/issues/2022/04…
1. Our co-chairs Matthew Edwards and @ActuaryByDay are interviewed by editor Ruolin Wang. The wide-ranging discussion includes the work of @COVID19actuary and the CMI, the media, the future, juggling, and Batman villains.
theactuary.com/2022/04/04/imp…
theactuary.com/2022/04/04/imp…
2. Dr @ARegenauer presents an overview of the latest #LongCovid research, and suggests a plausible subgrouping of this multifaceted post-viral condition. He considers what we we have learned, and just how much is still not known.
theactuary.com/features/2022/…
theactuary.com/features/2022/…
Our 63rd Friday Report is now available covering recent developments with vaccines, treatments and data.
In this edition (thread):
•Vaccine safety results
•Duration of mRNA vaccine protection against Omicron
covidactuaries.org/2022/03/18/the…
In this edition (thread):
•Vaccine safety results
•Duration of mRNA vaccine protection against Omicron
covidactuaries.org/2022/03/18/the…
Also included:
•Road ahead for COVID vaccination
•BA.2 dominant in England
•Risk of severe outcomes – Omicron v Delta
•Evusheld as vaccine alternative
•More evidence Ivermectin doesn’t improve outcomes
•COVID-19 impact on brain function
covidactuaries.org/2022/03/18/the…
•Road ahead for COVID vaccination
•BA.2 dominant in England
•Risk of severe outcomes – Omicron v Delta
•Evusheld as vaccine alternative
•More evidence Ivermectin doesn’t improve outcomes
•COVID-19 impact on brain function
covidactuaries.org/2022/03/18/the…
Also included:
•Omicron survives longer on surfaces
•Worldwide excess mortality
•Transmissibility comparison – Omicron v Delta
•Infection studies (REACT and ONS)
•ONS antibody levels and COVID mortality
•UKHSA 28-day mortality vs ONS
covidactuaries.org/2022/03/18/the…
•Omicron survives longer on surfaces
•Worldwide excess mortality
•Transmissibility comparison – Omicron v Delta
•Infection studies (REACT and ONS)
•ONS antibody levels and COVID mortality
•UKHSA 28-day mortality vs ONS
covidactuaries.org/2022/03/18/the…
